CompletedPhase 2

Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients

Egypt104 participantsStarted 2019-03-01

Plain-language summary

Norfloxacin is the most commonly used drug for the prophylaxis against spontaneous bacterial peritonitis (SBP) in patients with liver cirrhosis. Rifaximin, another broad spectrum antibiotic with only trivial absorption from the gut, is used for the treatment of traveler's diarrhea and prevention of hepatic encephalopathy.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Decompensated cirrhotic patients (Child B or C, ascetic patients).
✓. Adult male/female aged \>18 years old.
✓. History or evidence of previous attack of SBP and currently clinically free from SBP.

Exclusion criteria

✕. Recent abdominal surgery.
✕. Patients with renal impairment (serum creatinine \>1.5mg/dl) at baseline.
✕. Patients on renal replacement therapy (RRT) at baseline.
✕. Sonographic evidence of Nephropathy other than grade I nephropathy in ascetic patients
✕. intraabdominal source of infection (e.g. intra-abdominal abscesses, cholecystitis or acute pancreatitis).
✕. Patients with current evidence of upper Urinary tract infection.
✕. Other comorbidities affecting the patient survival e.g. significant cardiac disease, pulmonary disease, portal vein thrombosis, hepatocellular carcinoma or other malignancies, etc.
✕. Sepsis.

What they're measuring

secondary prophylaxis of SBP and primary prophylaxis for hepatorenal syndrome

Timeframe: 3 months

Trial details

NCT IDNCT05621005

SponsorSamar Atef Sebaweh Mohammed

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-07-01

View on ClinicalTrials.gov More Ascites Infection trials